Cyclic adenosine 3',5'-monophosphate binding proteins in human colorectal cancer and mucosa.
Cyclic AMP Binding Proteins (cAMP-BP) levels have been measured by means of a competitive binding assay in the cytosols of 50 human colorectal cancers. These levels have been related to those in mucosa both adjacent to and distant from the tumour in the same patients. Cyclic AMP-BP were higher in tumour than in either adjacent (P less than 0.000001) or distant mucosa (P less than 0.00001). Binding of cAMP in adjacent mucosa was lower than that in distant mucosa (P less than 0.0001). There was no significant difference in the level of binding between tumours arising from different sites in the colon and binding was not related to age or sex of the patient. However, binding was higher in Dukes' B than Dukes' C cancers (P less than 0.005). There was also a trend for cAMP binding levels to be higher in moderately differentiated than in poorly differentiated cancers (P = 0.07). Thus cAMP-BP appear to be over-expressed in human colorectal cancers and levels are related to the stage and grade.
Bradbury
A W
AW
University Department of Clinical Surgery, Royal Infirmary, Edinburgh, UK.
Miller
W R
WR
Carter
D C
DC
D000368:Aged; D002352:Carrier Proteins / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000473:pathology; D000242:Cyclic AMP / Q000378:metabolism*; D002373:Cyclic AMP Receptor Protein; D003600:Cytosol / Q000378:metabolism; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging
D002352:Carrier Proteins; D002373:Cyclic AMP Receptor Protein; D000242:Cyclic AMP